Endometrial carcinomas: Correlation between ER, PR, Ki67 status and histopathological prognostic parameters

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 2, 2011, Pages 631-636

  Stoian, Sidonia Cǎtǎlina ^a   Simionescu, Cristiana ^b   Mǎrgǎritescu, Cl ^b   Stepan, A ^b   Nurciu, M ^a  

^a Emergency County Hospital   (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Endometrial carcinomas; ER; Ki67; PR

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS;

CELL DIFFERENTIATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79959354867     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parker SL, Tong T, Bolden S, Wingo PA, Cancer statistics, 1996, CA Cancer J Clin, 1996, 46(1):5-27.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ, Cancer statistics, 2007, CA Cancer J Clin, 2007, 57(1):43-66.
3. Carcangiu ML, Chambers JT, Voynick IM, Pirro M, Schwartz PE, Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations, Am J Clin Pathol, 1990, 94(3):247-254.
4. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P, Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression, Virchows Arch, 2001, 438(5):470-477.
5. Bokhman JV, Two pathogenetic types of endometrial carcinoma, Gynecol Oncol, 1983, 15(1):10-17.
6. Prat J, Prognostic parameters of endometrial carcinoma, Hum Pathol 2004, 35(6):649-662.
7. Kauppila A, Jänne O, Kujansuu E, Vihko R, Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels, Cancer, 1980, 46(10):2162-2167.
8. Mutter GL, Ince TA, Molecular pathogenesis of endometrial cancer. In: Fuller A, Seiden MV, Young R (eds), Uterine cancers: American Cancer Society atlas of clinical oncology, 1st edition, B.C. Decker, Hamilton (Ontario, Canada), 2004, 10-21.
9. Horn LC, Meinel A, Handzel R, Einenkel J, Histopathology of endometrial hyperplasia and endometrial carcinoma: an update, Ann Diagn Pathol, 2007, 11(4):297-311.
10. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA, Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type, Histopathology, 2004, 44(5):472-479.
11. Hoskins WJ, Perez CA, Young RC, Principles and practice of gynecologic oncology, Lippincott Williams & Wilkins, Philadelphia, 2000, 1005-1007.
12. Kim JW, Kim SH, Kim YT, Kim DK, Clinicopathologic and biological parameters predicting the prognosis in endometrial cancer, Yonsei Med J, 2002, 43(6):769-778.
13. Ferrandina G, Ranelletti FO, Larocca LM, Maggiano N, Fruscella E, Legge F, Santeusanio G, Bombonati A, Mancuso S, Scambia G, Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer, Clin Cancer Res, 2001, 7(9):2656-2661.
14. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T, Konishi I, Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumorsuppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator, Hum Pathol, 2003, 34(5):471-478.
15. Suthipintawong C, Wejaranayang C, Vipupinyo C, Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma, J Med Assoc Thai, 2008, 91(12):1779-1784.
16. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I, Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas, Eur J Cancer, 2007, 43(16):2434-2444.
17. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H, Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma, Gynecol Oncol, 1998, 69(3):220-225.
18. Singh M, Zaino RJ, Filiaci VJ, Leslie KK, Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study, Gynecol Oncol, 2007, 106(2):325-333.
19. Nyholm HC, Endometrial cancer and steroid hormone receptors, Ugeskr Laeger, 1990, 152(9):593-597.
20. Bergeron C, Ferenczy A, Shyamala G, Distribution of estrogen receptors in various cell types of normal, hyperplastic, and neoplastic human endometrial tissues, Lab Invest, 1988, 58(3):338-345.
21. Jokanović L, Cvrtila D, Klarić P, Kanajet D, Levels of estrogen and progesterone receptors in premalignant and malignant states in the endometrium, Jugosl Ginekol Perinatol, 1991, 31(3-4):49-51.
22. Uchikawa J, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Oka K, Konishi I., Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression, Cancer, 2003, 98(10):2207-2213.
23. Stenchever MA, Mishell D, Herbst AL, Droegemueller W, Comprehensive gynecology, Elsevier Health Sciences, 2001.
24. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, Scambia G, Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer, Gynecol Oncol, 2005, 98(3):383-389.
25. Nyholm HC, Nielsen AL, Lyndrup J, Norup P, Thorpe SM, Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlation with stage and other clinicopathologic features, Am J Obstet Gynecol, 1992, 167(5):1334-1342.
26. Friberg LG, Norén H, Prognostic value of steroid hormone receptors for 5-year survival in stage II endometrial cancer, Cancer, 1993, 71(11):3570-3574.
27. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A, Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer, Int J Gynecol Cancer, 2002, 12(3):286-289.
28. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE, Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer, Gynecol Oncol, 1988, 31(1):65-81.
29. Salvesen HB, Iversen OE, Akslen LA, Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study, J Clin Oncol, 1999, 17(5):1382-1390.
30. Gassel AM, Backe J, Krebs S, Schön S, Caffier H, Müller-Hermelink HK, Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome, J Clin Pathol, 1998, 51(1):25-29.
31. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C, Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients, Gynecol Oncol, 1996, 61(1):16-21.
32. Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geisler HE, Proliferation index determined by MIB-1 and recurrence in endometrial cancer, Gynecol Oncol, 1996, 61(3):373-377.